The data shown below were collected from the profiles of 35 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
| Title |
Cholinesterase inhibitors for Alzheimer's disease
|
|---|---|
| Published in |
Cochrane database of systematic reviews, January 2006
|
| DOI | 10.1002/14651858.cd005593 |
| Pubmed ID | |
| Authors |
Jacqueline S Birks |
| Abstract |
Since the introduction of the first cholinesterase inhibitor (ChEI) in 1997, most clinicians and probably most patients would consider the cholinergic drugs, donepezil, galantamine and rivastigmine, to be the first line pharmacotherapy for mild to moderate Alzheimer's disease.The drugs have slightly different pharmacological properties, but they all work by inhibiting the breakdown of acetylcholine, an important neurotransmitter associated with memory, by blocking the enzyme acetylcholinesterase. The most that these drugs could achieve is to modify the manifestations of Alzheimer's disease. Cochrane reviews of each ChEI for Alzheimer's disease have been completed (Birks 2005, Birks 2005b and Loy 2005). Despite the evidence from the clinical studies and the intervening clinical experience the debate on whether ChEIs are effective continues. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 17% |
| Russia | 2 | 6% |
| Netherlands | 1 | 3% |
| Myanmar | 1 | 3% |
| Japan | 1 | 3% |
| Kazakhstan | 1 | 3% |
| Samoa | 1 | 3% |
| Canada | 1 | 3% |
| United Kingdom | 1 | 3% |
| Other | 1 | 3% |
| Unknown | 19 | 54% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 27 | 77% |
| Practitioners (doctors, other healthcare professionals) | 5 | 14% |
| Scientists | 2 | 6% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 1,212 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 8 | <1% |
| United States | 6 | <1% |
| Netherlands | 2 | <1% |
| Italy | 2 | <1% |
| Pakistan | 1 | <1% |
| Ireland | 1 | <1% |
| Switzerland | 1 | <1% |
| Sweden | 1 | <1% |
| Brazil | 1 | <1% |
| Other | 5 | <1% |
| Unknown | 1184 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 185 | 15% |
| Student > Ph. D. Student | 151 | 12% |
| Student > Master | 142 | 12% |
| Researcher | 127 | 10% |
| Student > Doctoral Student | 62 | 5% |
| Other | 193 | 16% |
| Unknown | 352 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 247 | 20% |
| Agricultural and Biological Sciences | 103 | 8% |
| Neuroscience | 94 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 67 | 6% |
| Biochemistry, Genetics and Molecular Biology | 66 | 5% |
| Other | 236 | 19% |
| Unknown | 399 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 100. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 February 2024.
All research outputs
#435,599
of 25,972,223 outputs
Outputs from Cochrane database of systematic reviews
#724
of 13,170 outputs
Outputs of similar age
#830
of 172,626 outputs
Outputs of similar age from Cochrane database of systematic reviews
#2
of 59 outputs
Altmetric has tracked 25,972,223 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 98th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,170 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 34.5. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 172,626 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 59 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.